Serina Therapeutics, Inc.
SER
$5.65
$0.152.73%
AMEX
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -95.90% | -98.37% | -98.22% | 2,454.21% | 2,368.48% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -95.90% | -98.37% | -98.22% | 2,454.21% | 2,368.48% |
| Cost of Revenue | 158.50% | 201.29% | 213.23% | 248.60% | 168.75% |
| Gross Profit | -935.93% | -28,203.03% | -1,070.46% | -78.63% | 27.82% |
| SG&A Expenses | 110.71% | 236.58% | 255.03% | 175.90% | 162.15% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 133.11% | 218.43% | 233.72% | 205.86% | 165.20% |
| Operating Income | -258.14% | -561.44% | -917.78% | -137.53% | -78.31% |
| Income Before Tax | -79.86% | 91.11% | -312.70% | -304.55% | -689.44% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -79.86% | 91.11% | -312.70% | -304.55% | -689.44% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 129.63% | -- | -- | -- | -- |
| Net Income | -79.67% | 91.77% | -311.44% | -303.06% | -687.18% |
| EBIT | -258.14% | -561.44% | -917.78% | -137.53% | -78.31% |
| EBITDA | -264.56% | -578.97% | -967.92% | -139.90% | -77.44% |
| EPS Basic | 55.26% | 91.67% | -319.26% | -351.81% | -749.90% |
| Normalized Basic EPS | 34.83% | 100.35% | -470.20% | 2.05% | -56.29% |
| EPS Diluted | 70.49% | 96.85% | -823.33% | -1,853.13% | -1,486.91% |
| Normalized Diluted EPS | 42.15% | 95.83% | -4,311.33% | -252.00% | -227.27% |
| Average Basic Shares Outstanding | 196.41% | 377.38% | 332.74% | 160.15% | 84.32% |
| Average Diluted Shares Outstanding | 79.72% | 100.26% | 39.17% | 18.36% | 34.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |